PledPharma strengthens its organization
September 20, 2011
PledPharma AB Company Announcement PledPharma strengthens its organization Stockholm, 2011-09-20 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma (STO:PLED) today announced that they have recruited Marie Bengtson to lead clinical projects, and Erik Kinnman as accountable for investor relations and clinical expert. Marie Bengtson has 14 years of clinical development experience within the pharmaceutical industry. This experience includes the international research companies Merck-Serono and Sanofi-Aventis, and the world leading contract research organization, Quintiles. Marie has considerable experience of project management, planning, execution and reporting of clinical trials within cancer, cardiovascular diseases, diabetes, and diseases in the nervous system. She has been involved in early as well as late clinical trials. Moreover, she has 16 years of background as an operating room nurse. Marie most recently worked at IRW Consulting AB, where she served as a Clinical Research Manager and Nordic project leader. Erik Kinnman has 13 years of clinical experience from the pharmaceutical industry, which includes leadership positions within AstraZeneca, Sanofi-Synthelabo and Parke-Davies. Erik has also for several years been the head of a life science analyst team at Danske Bank, and fund manager at Aragon Fondkommission. Erik has earned MBA, PhD and Medical Doctor degrees, and holds an associate professor position in experimental and clinical pain research. He is also a board certified specialist in neurology and pain management. Erik most recently worked at SOBI, where he was accountable for investor relations, communication, and corporate strategy. ”These recruitments are an important increase in PledPharma's expertise and resources. We are approaching important clinical development milestones and the additions of Marie and Erik to our organization are very timely. In addition, the company's expertise within investor relations is strengthened at a point in time when the interest for our activities are expected to increase considerably, and thereby the need for communication with shareholders and new investors”, commented CEO Jacques Näsström. For further information please contact: Jacques Näsström, CEO, cell: +46 73 713 0979 Erik Kinnman, Investor relations, cell: +46 73 422 1540 About PledPharma PledPharma is a Swedish specialty pharma company, focused on developing improved treatments of life-threatening diseases. The company's products may increase the efficiency of established therapies by reducing serious side effects and improving quality of life. PledPharma are currently running two phase II clinical projects with patented PLED-derivative compounds. The ability of PLED-derivatives to reduce the side effects that arise in chemotherapy treatment of colon cancer is examined in one of the projects, PP-095. The possible reduction of reperfusion injuries in acute myocardial infarction patients undergoing percutaneous coronary intervention (PCI) is evaluated in the other project, PP-099. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For more information, please visit www.pledpharma.se
